Marketing-authorisation holder · Canada
Vertex Pharmaceuticals (Canada) Incorporated
19 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Canada
19 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
19 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALYFTREK50 mg + 20 mg + 4 mg · Tablet | Deutivacaftor, Tezacaftor, Vanzacaftor | Canada | Marketed | 2025 |
| ALYFTREK125 mg + 50 mg + 10 mg · Tablet | Deutivacaftor, Tezacaftor, Vanzacaftor | Canada | Marketed | 2025 |
| CASGEVY13000000 cells / ml · Suspension | Exagamglogene autotemcel | Canada | Authorised | |
| KALYDECO13.4 mg / sachet · Granules | Ivacaftor | Canada | Marketed | 2023 |
| KALYDECO150 mg · Tablet | Ivacaftor | Canada | Marketed | 2012 |
| KALYDECO25 mg / sachet · Granules | Ivacaftor | Canada | Marketed | 2021 |
| KALYDECO50 mg / sachet · Granules | Ivacaftor | Canada | Marketed | 2015 |
| KALYDECO75 mg / sachet · Granules | Ivacaftor | Canada | Marketed | 2015 |
| ORKAMBI125 mg + 200 mg · Tablet | Ivacaftor, Lumacaftor | Canada | Marketed | 2016 |
| ORKAMBI94 mg / sachet + 75 mg / sachet · Granules | Ivacaftor, Lumacaftor | Canada | Marketed | 2023 |
| ORKAMBI125 mg + 100 mg · Tablet | Ivacaftor, Lumacaftor | Canada | Marketed | 2017 |
| ORKAMBI125 mg / sachet + 100 mg / sachet · Granules | Ivacaftor, Lumacaftor | Canada | Marketed | 2018 |
| ORKAMBI188 mg / sachet + 150 mg / sachet · Granules | Ivacaftor, Lumacaftor | Canada | Marketed | 2018 |
| SYMDEKO150 mg + 150 mg + 100 mg · Tablet | Ivacaftor, Tezacaftor | Canada | Marketed | 2018 |
| TRIKAFTA100 mg + 75 mg + 75 mg + 50 mg · Granules | Elexacaftor, Ivacaftor, Tezacaftor | Canada | Marketed | 2023 |
| TRIKAFTA100 mg + 75 mg + 150 mg + 50 mg · Tablet | Elexacaftor, Ivacaftor, Tezacaftor | Canada | Marketed | 2021 |
| TRIKAFTA80 mg + 60 mg + 59.5 mg + 40 mg · Granules | Elexacaftor, Ivacaftor, Tezacaftor | Canada | Marketed | 2023 |
| TRIKAFTA50 mg + 75 mg + 37.5 mg + 25 mg · Tablet | Elexacaftor, Ivacaftor, Tezacaftor | Canada | Marketed | 2022 |
| INCIVEK375 mg · Tablet | Telaprevir | Canada | Cancelled | 2011 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 19 | 18 | 1 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.